626 Improving the yeast transformation efficiency for yeast display in antibody development

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A662-A662
Author(s):  
Jian Chen ◽  
George Sun

BackgroundIn the therapeutic antibody development process, the yeast display technology which expresses a large library of antibodies is very useful for increasing the affinity of a lead antibody. Ideally, a yeast library should exceed the size of 10E10 to 10E11 to get close to the real affinity maturation process. However, due to low transformation efficiency with yeast, it requires trememdous scaling-up efforts to simply reach the 10E9 library size.MethodsTo address the transformation problem, we developed a new electroporation device that applies a high voltage on a sealed electroporation tube containing the yeast and plasmids in a low conductance buffer.ResultsThe new device is arcing free due to the sealed design and each single reaction could generate 10E8 library size, far exceeding the 10E6 size that was previously reported in a single reaction.ConclusionsWith the improved transformation efficiency, it becomes very straightforward to reach the currently difficult size of 10E9. Further more, it is possible to reach the 10E10 to 10E11 library size with reaction scaling-up. Our new method could be very useful for the field of antibody development.

Viruses ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 568
Author(s):  
Godwin W. Nchinda ◽  
Nadia Al-Atoom ◽  
Mamie T. Coats ◽  
Jacqueline M. Cameron ◽  
Alain Bopda Waffo

Phage display technology involves the surface genetic engineering of phages to expose desirable proteins or peptides whose gene sequences are packaged within phage genomes, thereby rendering direct linkage between genotype with phenotype feasible. This has resulted in phage display systems becoming invaluable components of directed evolutionary biotechnology. The M13 is a DNA phage display system which dominates this technology and usually involves selected proteins or peptides being displayed through surface engineering of its minor coat proteins. The displayed protein or peptide’s functionality is often highly reduced due to harsh treatment of M13 variants. Recently, we developed a novel phage display system using the coliphage Qβ as a nano-biotechnology platform. The coliphage Qβ is an RNA phage belonging to the family of Leviviridae, a long investigated virus. Qβ phages exist as a quasispecies and possess features making them comparatively more suitable and unique for directed evolutionary biotechnology. As a quasispecies, Qβ benefits from the promiscuity of its RNA dependent RNA polymerase replicase, which lacks proofreading activity, and thereby permits rapid variant generation, mutation, and adaptation. The minor coat protein of Qβ is the readthrough protein, A1. It shares the same initiation codon with the major coat protein and is produced each time the ribosome translates the UGA stop codon of the major coat protein with the of misincorporation of tryptophan. This misincorporation occurs at a low level (1/15). Per convention and definition, A1 is the target for display technology, as this minor coat protein does not play a role in initiating the life cycle of Qβ phage like the pIII of M13. The maturation protein A2 of Qβ initiates the life cycle by binding to the pilus of the F+ host bacteria. The extension of the A1 protein with a foreign peptide probe recognizes and binds to the target freely, while the A2 initiates the infection. This avoids any disturbance of the complex and the necessity for acidic elution and neutralization prior to infection. The combined use of both the A1 and A2 proteins of Qβ in this display system allows for novel bio-panning, in vitro maturation, and evolution. Additionally, methods for large library size construction have been improved with our directed evolutionary phage display system. This novel phage display technology allows 12 copies of a specific desired peptide to be displayed on the exterior surface of Qβ in uniform distribution at the corners of the phage icosahedron. Through the recently optimized subtractive bio-panning strategy, fusion probes containing up to 80 amino acids altogether with linkers, can be displayed for target selection. Thus, combined uniqueness of its genome, structure, and proteins make the Qβ phage a desirable suitable innovation applicable in affinity maturation and directed evolutionary biotechnology. The evolutionary adaptability of the Qβ phage display strategy is still in its infancy. However, it has the potential to evolve functional domains of the desirable proteins, glycoproteins, and lipoproteins, rendering them superior to their natural counterparts.


1992 ◽  
Vol 6 (2) ◽  
pp. 105-108
Author(s):  
Jacob Sajet

The article examines the university-enterprise relationship through six scenarios. Consistent problems, such as the reluctance of industry to become involved in the early stages of a project and the tendency of universities to be relatively uninterested in scaling up, are outlined. Various solutions are proposed, such as the establishment of ‘incubator-type’ units within universities in order to speed up the development process.


2019 ◽  
Vol 9 (5) ◽  
pp. 960-972 ◽  
Author(s):  
Wei Sun ◽  
Zhaona Yang ◽  
Heng Lin ◽  
Ming Liu ◽  
Chenxi Zhao ◽  
...  

2018 ◽  
Vol 8 (5) ◽  
pp. e00730 ◽  
Author(s):  
Sheng‐Chun Yu ◽  
Florian Kuemmel ◽  
Maria‐Nefeli Skoufou‐Papoutsaki ◽  
Pietro D. Spanu

2012 ◽  
Vol 26 (2) ◽  
pp. 101-112 ◽  
Author(s):  
B. J. Tillotson ◽  
I. F. de Larrinoa ◽  
C. A. Skinner ◽  
D. M. Klavas ◽  
E. V. Shusta

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Sheng-Chun Yu ◽  
Alexander Dawson ◽  
Alyssa C. Henderson ◽  
Eloise J. Lockyer ◽  
Emily Read ◽  
...  

2020 ◽  
Author(s):  
Han Lei ◽  
Bowen Xie ◽  
Tong Gao ◽  
Qianhong Cen ◽  
Yi Ren

Abstract Background Existing methods for preparing influenza vaccines pose the greatest challenge against highly pandemic avian influenza H7N9 outbreak in the poultry and humans. Exploring a new strategy for manufacturing and delivering a safe and effective H7N9 vaccine is needed urgently. Results An alternative approach is to develop an influenza H7N9 oral vaccine based on yeast display technology in a timely manner. Hemagglutinin (HA) of A/Anhui/1/2013 (AH-H7N9) is used as a model antigen and characterized its expression on the surface of Saccharomyces cerevisiae (S.cerevisiae) EBY 100. Mice administrated orally with S.cerevisiae EBY100/pYD5-HA produced significant titers of IgG antibody as well as significant amounts of cytokines IFN-γ and IL-4. Importantly, S.cerevisiae EBY100/pYD5-HA could provide effective immune protection against homologous A/Anhui/1/2013 (AH-H7N9) virus challenge. Conclusions Our findings suggest that platform based on yeast surface technology provides an alternative approach to prepare a promising influenza H7N9 oral vaccine candidate that can significantly shorten the preparedness period and result in effective protection against influenza A pandemic. Keywords: S.cerevisiae EBY100/pYD5-HA, Yeast display technology, Influenza A pandemic.


2018 ◽  
Author(s):  
Marvin H. Gee ◽  
Xinbo Yang ◽  
K. Christopher Garcia

ABSTRACTT cell receptors (TCRs) exhibit varying degrees of cross-reactivity for peptides presented by the human leukocyte antigen (HLA). In engineered T cell therapies, TCR affinity maturation is a strategy to improve the sensitivity and potency to often a low-density peptide-HLA (pHLA) target. However, the process of affinity maturation towards a known pHLA complex can introduce new and untoward cross-reactivities that are difficult to detect and raises significant safety concerns. We developed a yeast-display platform of pHLA consisting of ~100 million different 9mer peptides presented by HLA-A*01 and used a previously established selection approach to validate the specificity and cross-reactivity of the A3A TCR, an affinity-matured TCR against the MAGE-A3 target (EVDPIGHLY). We were able to identify reactivity against the titin peptide (ESDPIVAQY), to which there is now known clinical toxicity. We propose the use of yeast-display of pHLA libraries to determine cross-reactive profiles of candidate clinical TCRs to ensure safety and pHLA specificity of natural and affinity-matured TCRs.


Sign in / Sign up

Export Citation Format

Share Document